Disease activation and laboratory parameters in Fibromyalgia Syndrome: Relationship with C-reactive protein/albumin ratio, neutrophil/lymphocyte ratio, mean platelet volume
Melih Pamukcu, Rabia Aydogan Baykara, Tugba Izci Duran
Fibromyalgia syndrome (FMS) is a chronic, widespread painful disease with unexplained etiopathogenesis and somatic-psychic findings. Unlike inflammatory rheumatic diseases, there are no specific laboratory parameters in FMS. In our study, we aimed to investigate the relationship between inflammatory markers and FMS activation scales. Eighty patients aged 18-65 years, diagnosed with FSM according to the American College of Rheumatology (ACR) 1990 criteria, were evaluated retrospectively. 61 healthy controls matched for sex, age, and body mass index (BMI) constituted the control group. In addition to the demographic data of the patients, the fibromyalgia impact questionnaire (FIQ) score, visual analog scale (VAS) fatigue score, VAS pain score, number of tender points, C- reactive protein (CRP), erythrocyte sedimentation rate (ESR), albumin, and complete blood count values were evaluated and compared statistically. FIQ, VAS pain, and VAS fatigue score, number of tender points were significantly higher in the patient group (p<0.001). The mean platelet volume (MPV), neutrophil-lymphocyte ratio (NLR), CRP values of the patient group were not statistically different from the control group. Patients’ FIQ, VAS pain and VAS fatigue scores, number of tender points, and MPV, NLR, and CRP albumin ratio (CAR) parameters were not significant according to the correlation analysis. FIQ, VAS pain, VAS fatigue scores, and the number of tender points were statistically higher in the patient group, MPV, NLR, and CAR parameters were not different. Contrary to studies stating that FMS may be of inflammatory origin, no statistically significant difference was found in inflammatory disease activation parameters between patients with FMS and the control group in our study.
Key words: Femoral artery, hemorrhage, bleeding, algan hemostatic agent, celox